# PTRY

Source: https://onco.cc/drugs/ptry/  
OnCo record `ptry` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PTRY is an experimental trispecific T-cell engager from Chiome Bioscience, in preclinical development for malignant mesothelioma, small cell lung cancer and non-small cell lung cancer and other cancers.

## Summary

PTRY is a trispecific T-cell engager (Tribody: 5T4, CD3 and PD-L1) from Chiome Bioscience. A humanized 5T4/CD3/PD-L1 multispecific antibody built with Tribody technology, which has three binding sites. Its furthest stage is preclinical development, for malignant mesothelioma, small cell lung cancer, non-small cell lung cancer and triple-negative breast cancer. No clinical trial naming it is registered on ClinicalTrials.gov. Pipeline page: 'Data is being obtained for outsourcing'. It has not been shown to work in people.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-03
- Tags: pipeline
- Code: PTRY
- Modality: Trispecific T-cell engager (Tribody: 5T4, CD3 and PD-L1)
- Mechanism: A humanized 5T4/CD3/PD-L1 multispecific antibody built with Tribody technology, which has three binding sites.

## Sources

- Chiome Bioscience: chiome.co.jp: https://www.chiome.co.jp/en/pipeline/

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [CD3](https://onco.cc/targets/cd3/), [PD-L1](https://onco.cc/targets/pdl1/)
- companies: [Chiome Bioscience](https://onco.cc/companies/chiome-bioscience/)

---
JSON: https://onco.cc/api/v1/entities/ptry.json